Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 12/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807328 | 0.82 | NPC1 (0.56) | — | |
| SCHEMBL23021932 | 0.79 | ROCK2 (0.70) | ROCK2ROCK1P2RX7 | |
| SCHEMBL20868817 | 0.77 | ROCK2 (0.48) | ROCK2ROCK1 | |
| SCHEMBL11118544 | 0.76 | TP53 (0.52) | ROCK2ROCK1TSHR | |
| SCHEMBL21724695 | 0.73 | HSD11B1 (0.58) | P2RX7HSD11B1 | |
| SCHEMBL5643080 | 0.73 | SMN1; SMN2 (0.57) | ROCK2ROCK1P2RX7HSD11B1 | |
| SCHEMBL2831744 | 0.72 | P2RX7 (0.56) | P2RX7HSD11B1 | |
| SCHEMBL6357659 | 0.72 | TP53 (0.56) | ROCK2ROCK1P2RX7 | |
| SCHEMBL3232365 | 0.72 | MEN1 (0.51) | ROCK2ROCK1 | |
| SCHEMBL30363999 | 0.71 | GLS (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320994-B2 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | TACR1, TACR2, BDKRB1 | ROCK2 3674/4885ROCK1 1377/4885P2RX7 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.